miRNA Plasmid Composition for Kinase mRNA Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Over-expression or mis-expression of kinases leads to homeostasis disruption and associated diseases, necessitating therapies to regulate gene expression and suppress these biomolecules.
Innovation Solution
Compositions comprising plasmids with nucleotide sequences encoding miRNA sequences that target and degrade or inactivate the mRNA of kinases, such as Bruton's tyrosine kinase, EGF, VEGF, BRAF, ALK, HER, FLT3, or PARP, to downregulate their expression and production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If kinases are over-expressed or mis-expressed, then biological activity is increased, but homeostasis is lost and disease occurs
Solution Approach 1:
The patent extracts and utilizes miRNA sequences that naturally target and degrade kinase mRNA. By introducing these specific miRNA sequences into cells via plasmids, the invention selectively removes excess or mis-expressed kinases from the cellular proteome, thereby restoring homeostasis without affecting other biological functions.
Solution Approach 2:
The patent employs miRNA as an intermediary molecule between the plasmid and the kinase target. The miRNA sequences act as mediators that bind to kinase mRNA and facilitate its degradation, providing a controlled and specific mechanism for suppressing kinase expression while maintaining cellular homeostasis.
2Reliability
If therapies are developed to suppress over-expressed kinases, then homeostasis is restored, but gene expression regulation complexity increases
Solution Approach 1:
The patent employs miRNA sequences that are naturally part of the cell's regulatory system. By introducing these endogenous miRNA sequences through plasmids, the invention allows the cell's own gene expression machinery to perform the suppression function, avoiding the need for complex external therapeutic agents or proteins.
Solution Approach 2:
The patent changes the parameter of gene expression regulation by introducing specific miRNA sequences that alter the stability and translation of kinase mRNA. This parameter change enables precise control over kinase levels through RNA interference mechanisms, simplifying the overall therapeutic approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively decrease the bioavailability of target kinases, restoring homeostasis and potentially treating associated diseases by increasing endogenous production of miRNA sequences that target and silence the mRNA of these kinases.
Implementation Method 1
The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule
Implementation Method 2
a backbone sequence of nucleic acids that facilitates introduction of the one or more insert sequences into one or more of a subject's cells where it is expressed and/or replicated
Implementation Method 3
Expression of the one or more insert sequences by one or more cells of the subject results in an increased production of the miRNA
Data Source
AI summary
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a kinase.